Research Progress of Non-coding RNA in Multiple Myeloma with Heart Disease---Review.
10.19746/j.cnki.issn.1009-2137.2021.05.051
- Author:
Man-Ya YU
1
;
Su-Mei LI
1
;
Xing CUI
2
Author Information
1. College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine,Jinan 250011, Shandong Province, China.
2. Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong Province, China E-mail: cdz45@163.com.
- Publication Type:Journal Article
- MeSH:
Cardiovascular Diseases;
Heart Diseases;
Humans;
Multiple Myeloma/genetics*;
Prognosis;
RNA, Untranslated/genetics*
- From:
Journal of Experimental Hematology
2021;29(5):1680-1684
- CountryChina
- Language:Chinese
-
Abstract:
Some non-coding RNAs (ncRNA), as functional RNA molecules, lack potential to encode proteins, but can affect gene expression and disease progression through a variety of mechanisms. In multiple myeloma (MM), cardiovascular disease is one of the most common complications, which may be related to a variety of factors, including patient's own factors, disease-related factors, drug factors, etc. Non-coding RNA is considered to be an important regulator of cardiovascular event risk factors and cell function, and an important candidate target for improving the condition and prognostic assessment. This article briefly summarized the role of non-coding RNA in cardiac amyloidosis caused by MM, damage to the heart by inflammatory factors, and heart disease caused by chemotherapy drugs in recent years.
